The Brain, Mind and Pain (BMP) initiative has today launched its Book of Evidence for the 2019-2024 European Parliament term.
Get a glimpse of the key highlights, insights, and standout moments from EAN 2025 in Helsinki, all captured in our Congress Review eBook.
Latest Posts
-
-
On 27 March, the European Parliament and the Council reached an agreement on the EU's future framework programme for research and innovation, the Horizon Europe.
-
EBCOther News
News from EBC: publication integrating all voices in Spanish MS community released
May 1, 2019The publication “SumEMos: Análisis y propuestas para contribuir a normalizar la vida con EM” integrates all voices from the Multiple Sclerosis community in Spain. The document was released in the last weeks in conclusion of last year’s “SumEMos para normalizar la vida con EM” conference on 4 October. -
ECNP Networks and Thematic Working Groups (TWGs)
-
Petr Mikulenka, MD, from Prgaue, Czechia Fellowship Term: 18.06 - 27.07.2018 Hosting department: Department of Neurology, Atkinson Morley Wing, St George’s Hospital, Blackshaw Road, Tooting, London SW17 0QT Supervisor: Dr. Anthony Pereira, Consultant Neurologist
-
EAN Congress newsTop Articles
The BrainChallenge – second edition to take place in Oslo!
May 1, 2019Due to the successful debut of BrainChallenge in 2018, the EAN Teaching Course sub-Committee is organising the second edition of this entertaining and challenging Neurology Quiz during the upcoming EAN congress in Oslo in 2019. -
ResearchEur J Neurol
EUROPEAN JOURNAL OF NEUROLOGY – CONTRIBUTIONS FROM AUTHORS FROM SLOVENIA
May 1, 2019Please find below articles from authors from Slovenia and co-authors that were published in the European Journal of Neurology -
On 31 January 2019 , the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Ajovy©, intended for prophylaxis of migraine. The applicant for this medicinal product is Teva GmbH. The active substance is fremanezumab which is an antibody that works by binding to calcitonin gene-related peptide (CGRP). It is classified as an analgesic.
-
EAN NewsEAN NewsOther News
Conference Report: 17th Congress of the Academy for Multidisciplinary Neurotraumatology
May 1, 2019The 2019 Congress of the Academy for Multidisciplinary Neurotraumatology took place between April 11-12 in Cluj-Napoca, Romania, organized by the Foundation of the Society for the Study of Neuroprotection and Neuroplasticity and its partners. -
On 21 March (Madrid, Spain), the new Innovative Medicines Initiative (IMI) coordination and support action entitled “Efficiently Networking European Neurodegeneration Research” (NEURONET) held its kick-off meeting.
-
The BioMed Alliance has provided feedback to the public consultation on Plan S, the initiative of the European Commission, Research Funding Organisations and Science Europe to promote open access publishing.
-
EFNAOther News
News from EFNA: #BrainLifeGoals Grants for projects that raise awareness of brain disorder launched
May 1, 2019Sharing #LifeGoals has become a popular trend on social media. A campaign from the European Federation of Neurological Associations (EFNA) is putting a new spin on the trend by instead seeing patient advocates and supporters share their #BrainLifeGoals. -
On Tuesday, April 9, 2019, Active Citizenship Network (ACN) celebrated the 13th European Patients’ Rights Day (EPRD).
-
As in the previous years, EANpages asked EAN committee members, panel chairs, and invited speakers which session one should not miss at the upcoming congress in Oslo 2019. Please find their answers below!
-
Fragile X Syndrome (FXS), the most common genetic form of intellectual disability in males is caused by a ...